Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma

International Journal of Biological Markers

Volumn 26, Issue 4, 2011, Pages 229-233

  Ezzikouri, Sayeh ^a   El Feydi, Abdellah Essaid ^b   Afifi, Rajae ^b   Benazzouz, Mustapha ^b   Hassar, Mohammed ^a   Pineau, Pascal ^c   Benjelloun, Soumaya ^a  

^a Institut Pasteur du Maroc   (Morocco)

^b IBN SINA HOSPITAL   (Morocco)

^c INSERM   (France)

Author keywords

Hepatocellular carcinoma; MDM2; Moroccan; Polymorphism; TP53

Indexed keywords

ARGININE; GUANINE; PROLINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CODON; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENOTYPE; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MDM 2 GENE; MOROCCO; PROMOTER REGION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TP 53 GENE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CODON; FEMALE; GENE DOSAGE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOROCCO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 84555205744     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8881     Document Type: Article

References (12)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2005; 55: 74-108.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
3. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6: 909-23.
4. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119: 591-602.
5. Ohmiya N, Taguchi A, Mabuchi N, et al. MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006; 24: 4434-40.
6. Hirata H, Hinoda Y, Kikuno N, et al. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 2007; 13: 4123-9.
7. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. TP53 and liver carcinogenesis. Hum Mutat 2003; 21: 201-16.
8. Ezzikouri S, El Feydi AE, Chafik A, et al. The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res 2007; 37: 748-54.
9. Ezzikouri S, El Feydi AE, Afifi R, et al. MDM2 SNP309T>G polymorphism and risk of hepatocellular carcinoma: a case-control analysis in a Moroccan population. Cancer Detect Prev 2009; 32: 380-5.
10. Ezzikouri S, El Feydi AE, Benazzouz M, et al. Single nucleotide polymorphism in DNMT3B promoter and its association with hepatocellular carcinoma in a Moroccan population. Infect Genet Evol 2009; 9: 877-81.
11. Yoon YJ, Chang HY, Ahn SH, et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis 2008; 29: 1192-6.
12. Yang M, Guo Y, Zhang X, et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 2007; 28: 1996-2001.